The impact of chemotherapy on the care of patients with tuberculosis.
D000995:Antitubercular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D001500:BCG Vaccine; D001431:Bacteriological Techniques; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000009:adverse effects / Q000627:therapeutic use; D006760:Hospitalization; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects / Q000627:therapeutic use; D007902:Length of Stay; D009169:Mycobacterium tuberculosis / Q000302:isolation & purification; D010044:Outpatient Clinics, Hospital; D011718:Pyrazinamide / Q000627:therapeutic use; D012293:Rifampin / Q000009:adverse effects / Q000627:therapeutic use; D013307:Streptomycin / Q000627:therapeutic use; D013997:Time Factors; D014374:Tuberculin Test; D014397:Tuberculosis, Pulmonary / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology / Q000517:prevention & control
D000995:Antitubercular Agents; D001500:BCG Vaccine; D011718:Pyrazinamide; D004977:Ethambutol; D001241:Aspirin; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin